Dy comparing efficacy and security of dabigatran etexilate to common of
Dy comparing efficacy and safety of dabigatran etexilate to typical of care in pediatric individuals with venous thromboembolism (VTE) Young children 18 y old with history of VTE and a minimum of 1 danger aspect for continuation of anticoagulation therapy Age and weight proper dabigatran twice/ d dosing None Recurrence of VTE at six and 12 mo, important and minor bleeding Kids 6 mo to six y old that have been treated for at the least 2 mo with LMWH and/or VKA for VTE Age and weight LDHA Protein supplier suitable rivaroxaban after per day dosing None Neonates and infants six mo who’ve been treated for a minimum of five d with Ephrin-B1/EFNB1 Protein Source heparin and/or VKA for arterial or venous thrombosis Weight-adjusted rivaroxaban oral suspension (0.1 ) for 7d None Children aged 6 mo to 18 y old with confirmed VTE who receive initial treatment with heparin and call for anticoagulation for at the least 90 d Young children 2 mo to 12 y old with earlier VTE Rivaroxaban granules for oral suspension None Age- and weightappropriate rivaroxaban when every day dosing LMWH or VKA Incidence of major bleeding and clinically relevant nonmajor bleeding plasma concentration of rivaroxaban, anti-Xa activity NCT02197416 SeptemberOpen-label, randomized, parallel-group clinical trialChildren 18 y old with VTE Age and weight appropriate dabigatran twice/d dosing VKA or LMWH Combined: comprehensive thrombus resolution, recurrent VTE, and mortality related to VTE NCT01895777 SeptemberJuneAronis and HylekSafety of dabigatran etexilate in blood clot prevention in childrenOpen-label, single-arm potential cohort studyNovemberEINSTEIN Junior Phase II: oral rivaroxaban in young youngsters with venous thrombosisOpen-label, single-arm studyNCTJanuaryApril 2017 (outcomes pending)Rivaroxaban for remedy in venous or arterial thrombosis in neonatesOpen-label, single-arm studyNCTNovemberDecemberEINSTEIN Junior Phase III: oral rivaroxaban in young children with venous thrombosisMulticenter, open-label, active-controlled, randomized clinical trialSymptomatic recurrent venous thromboembolism, main and clinically relevant nonmajor bleeding Location under the curve and maximum observed drug concentrationNCTNovemberJulyPhase I study on rivaroxaban granules for oral suspension formulation in kids Neonates to 18 y old and any stable illness that are at threat for venous or arterial thrombusOpen-label, single-arm pharmacokinetics studyNCTNovemberDecemberJournal on the American Heart AssociationStudy to evaluate a single dose of apixaban in pediatric subjects at risk to get a thrombotic disorderOpen-label, single-arm studyApixaban solutionNoneArea below the curve, maximum observed drug concentration, and estimated time at which maximum plasma concentration occursNCTJanuaryOctoberContinuedEvidence Gaps of NOACsCONTEMPORARY REVIEWDOI: 10.1161/JAHA.117.Clinical Trial Patient Population Intervention Comparison Principal Outcome Registration Study Start Date Estimated Completion DateTable three. ContinuedTrialDesignAronis and HylekA study of your safety and effectiveness of apixaban in stopping blood clots in children with leukemia that have a central venous catheter and are treated with pegylated (PEG) L-asparaginase Kids 1218 y old who present with VTE and requiring anticoagulation for 12 wks Kids 18 y old who continue to demand anticoagulation therapy and will abstain in the use of nonsteroidal antiinflammatory medicines Age and weight suitable edoxaban when every day dosing None Children 18 y old with VTE requiring anticoagulation for 90 d who’ve received a minimum of five.
